[1] |
张天瑞,高文怡,姚娟. KDM3A沉默对人乳腺癌细胞系MDA-MB-231凋亡和侵袭能力的影响[J]. 基础医学与临床, 2021,41:33-37.
|
[2] |
Zhang YN, Xia KR, Li CY, et al. Review of breast cancer pathologigcal image processing[J]. Biomed Res Int, 2021, 2021:1994764. doi: 10.1155/2021/1994764.
|
[3] |
Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer[J]. Oncologist, 2004, 9:606-616.
|
[4] |
Hamaguchi M, Meth JL, von Klitzing C, et al. DBC2, a candidate for a tumor suppressor gene involved in breast cancer[J]. Proc Natl Acad Sci U S A, 2002, 99:13647-13652.
|
[5] |
Magni M, Buscemi G, Zannini L. Cell cycle and apop-tosis regulator 2 at the interface between DNA damage response and cell physiology[J]. Mutat Res Rev Mutat Res, 2018, 776:1-9.
|
[6] |
Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K, et al. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints[J]. Annu Rev Biochem, 2004, 73:39-85.
|
[7] |
German J, Sanz MM, Ciocci S, et al. Syndrome-causing mutations of the BLM gene in persons in the Bloom's Syndrome Registry[J]. Hum Mutat, 2007, 28:743-753.
|
[8] |
Kitano K. Structural mechanisms of human RecQ helicases WRN and BLM[J]. Front Genet, 2014, 5:366. doi: 10.3389/fgene.2014.00366.
|
[9] |
Wang XW, Tseng A, Ellis NA, et al. Functional interaction of p53 and BLM DNA helicase in apoptosis[J]. J Biol Chem, 2001, 276:32948-32955.
|
[10] |
El Khalki L, Maire V, Dubois T, et al. Berberine impairs the survival of triple negative breast cancer cells: cellular and molecular analyses[J]. Molecules (Basel, Switzerland), 2020, 25:506. doi: 10.3390/molecules25030506
|
[11] |
Nguyen GH, Dexheimer TS, Rosenthal AS, et al. A small molecule inhibitor of the BLM helicase modulates chromosome stability in human cells[J]. Chem Biol, 2013, 20:55-62.
|
[12] |
Han Y, Yu X, Li S, et al. New perspectives for resistance to PARP inhibitors in triple-negative breast cancer[J]. Front Oncol, 2020, 10:578095. doi: 10.3389/fonc.2020.578095.
|
[13] |
Helleday T, Bryant HE, Schultz N. Poly (ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy[J]. Cell Cycle, 2005, 4:1176-1178.
|
[14] |
Yi M, Dong B, Qin S, et al. Advances and perspectives of PARP inhibitors [J]. Exp Hematol Oncol, 2019, 8:29. doi: 10.1186/s40164-019-0154-9.
|